Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy

Ronald Yap, Dorina Veliceasa, Urban Emmenegger, Robert S. Kerbel, Laura M. McKay, Jack Henkin, Olga V. Volpert

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Fingerprint

Dive into the research topics of 'Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy'. Together they form a unique fingerprint.

Medicine & Life Sciences